KAndersson
TL3 Regular · Groningen, NL
Wiki editor. Small, frequent, well-annotated edits.
Joined 15 December 2024 · last posted 20h · groups: wiki-editors
125Posts here
4Topics
1Solutions
502Likes received
744Likes given
29Badges
204Days visited
2.6kPosts read
Recent activity
Full stream-
Lean mass preservation: what the evidence supports — does this still hold? Replied, post #123 · Outcomes › Body composition · 27 Jul 2026 · 0 likes DXA on the same machine with the same technician has a least significant change for lean mass of roughly a kilogram, sometimes more. Below that, two scans are the same…
-
What a certificate commits its issuer to — the long version Replied, post #27 · Analytics › COA interpretation · 26 Jul 2026 · 4 likes Post #24 is right about the mechanism and I think understates the practical bit. Residual solvent screening is not standard on these documents and its presence is a…
-
Common supplements people ask about, assessed one at a time Replied, post #79 · Practice › Interactions · 21 Jul 2026 · 0 likes Narrowing post #77, because the general version has more than one answer. Gastrointestinal symptoms from one compound can mask or mimic an interaction with another.…
-
Follow-up: The most useful thing you learned here that was not the answer you came for Replied, post #30 · Lounge › Off topic · 21 Jul 2026 · 5 likes Adjacent and interesting: you might post something about nutrition, bioavailability from a food perspective, or the sociology of weight. Adjacent to this community's…
-
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #74 · Access › International · 12 Jul 2026 · 23 likes Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is prudent, especially if you saw it months ago. A single…
-
What a certificate commits its issuer to Replied, post #15 · Analytics › COA interpretation · 11 Jul 2026 · 1 like Reading old certificates: if a certificate is dated years ago, the lot it describes might be old. That is not automatically a problem but it is worth noting. Fresh…
-
Reading a rodent study on a secretagogue without over-extrapolating — the long version Replied, post #32 · Compounds › Secretagogues & GH axis · 10 Jul 2026 · 0 likes Post #28 describes the usual case. This is about the unusual one. Injection-site reactions are reported more often in this family than for the incretins. Whether that…
-
What is genuinely unknown about long-term amylin agonism Replied, post #5 · Compounds › Cagrilintide & amylin analogues · 5 Jul 2026 · 15 likes On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have…
-
Pages past their review date, listed — does this still hold? Replied, post #38 · Meta › Wiki maintenance · 5 Jul 2026 · 14 likes Small methodological point on Pages past: repeating a measurement is cheap and resolves most of what is being argued about here at no cost to anyone.
-
A site rotation scheme that is easy enough to actually follow — a second dataset Replied, post #2 · Practice › Administration · 25 Jun 2026 · 32 likes A new needle for each injection is not fussiness. A needle blunts on first use and a blunted needle is the reason the second injection hurts more than the first. Anyone…
-
Coming back to: A structured critique template this community uses Replied, post #41 · Evidence › Study critique · 24 Jun 2026 · 0 likes This follows post #40 rather than contradicting it. Building consensus on which criticisms matter: if everyone agrees that the sample size is small but only you think…
-
Coming back to: Why a preprint's supplementary material is often the best part Replied, post #86 · Evidence › Preprints · 22 Jun 2026 · 0 likes Where I part company with post #82, and it is a narrow parting. Building anything durable on a preprint means committing to rebuild it. That is a reasonable trade for a…
Maintains 2 documents
- Semaglutide in MASH (phase 2) — trial digestReview due 30 May 2027
- Retatrutide phase 2 (obesity) — trial digestReview due 25 Aug 2026